Fibralign Corporation

Fibralign Corporation specializes in developing advanced therapeutic biomedical devices aimed at addressing critical unmet medical needs, particularly in soft tissue repair. Founded in 2007 in Union City, US, Fibralign Corporation focuses on innovative biomedical solutions. The company was established as a response to the lack of effective treatments for chronic conditions and is led by CEO Greg King. Fibralign has undergone a significant funding round in November 2017, marking an important milestone in its growth.

Fibralign is focused on developing innovative therapeutic biomedical devices to address significant unmet medical needs, with its flagship product being the BioBridge® Collagen Matrix. This device has received FDA 510(k) clearance for use in soft tissue repair and is currently being studied for its application in treating secondary lymphedema, a chronic condition that lacks a definitive cure. The BioBridge® technology utilizes the proprietary Nanoweave® scaffolding platform, which enables the creation of 3D scaffolding that closely resembles human tissue at a nanoscale, promoting effective healing and repair functions in the body. The primary end-users of Fibralign’s products include healthcare providers and patients affected by lymphedema and other soft tissue injuries, particularly in markets such as the United States and Europe, where the company has made its products commercially available.

Fibralign generates revenue through the sale of its BioBridge® Collagen Matrix, marketed primarily to healthcare institutions and professionals involved in surgical procedures and soft tissue repair. The business operates on a direct-to-consumer and business-to-business model, facilitating transactions directly with hospitals and clinics. Through these partnerships, Fibralign establishes contractual agreements that outline the terms for product supply and integration into clinical practices. The company’s pricing structure reflects its positioning in the medical device market, with flagship products like the BioBridge® Collagen Matrix being key components of its revenue stream.

As Fibralign expands its clinical studies and product offerings, including ongoing evaluations of BioBridge® for lymphedema treatment, the company continues to engage with various stakeholders in the healthcare sector to maximize accessibility and utilization of its innovative solutions. Fibralign Corporation intends to expand its product lineup by developing new therapeutic devices aimed at treating soft tissue injuries and exploring additional applications for the BioBridge® technology. The company is targeting expansion into European and Asian markets by 2025 in response to growing demand for innovative medical solutions. The funding raised in November 2017 will support these initiatives, allowing Fibralign to enhance research and development efforts and facilitate market entry.

As the company continues to assess and utilize its proprietary technologies, it aims to improve patient outcomes and broaden its impact on the healthcare community.